The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications

Research output: Contribution to conferenceOtherpeer-review

Authors

Details

Original languageEnglish
Publication statusPublished - 25 Mar 2017
EventEMDR Association UK & Ireland Annual Conference 2017 - London
Duration: 25 Mar 2017 → …

Conference

ConferenceEMDR Association UK & Ireland Annual Conference 2017
Period25/03/17 → …
Publication type

Research output: Contribution to conferenceOtherpeer-review

Abstract

Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.